These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 26115884)
21. Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer. Bouanene H; Hadj Kacem H; Ben Fatma L; Ben Limem H; Ben Ahmed S; Yakoub S; Miled A Pathol Oncol Res; 2011 Jun; 17(2):295-9. PubMed ID: 21046495 [TBL] [Abstract][Full Text] [Related]
22. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. Nunna S; Reinhardt R; Ragozin S; Jeltsch A PLoS One; 2014; 9(1):e87703. PubMed ID: 24489952 [TBL] [Abstract][Full Text] [Related]
23. Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer. van der Gun BT; de Groote ML; Kazemier HG; Arendzen AJ; Terpstra P; Ruiters MH; McLaughlin PM; Rots MG Br J Cancer; 2011 Jul; 105(2):312-9. PubMed ID: 21694727 [TBL] [Abstract][Full Text] [Related]
24. Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer. Pietzner K; Woopen H; Richter R; Joens T; Braicu EI; Dimitrova D; Mellstedt H; Darb-Esfahani S; Denkert C; Lindhofer H; Fotopoulou C; Sehouli J Int J Gynecol Cancer; 2013 Jun; 23(5):797-802. PubMed ID: 23694980 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study. Li YN; Li YY; Wang SX; Ma XY Curr Med Sci; 2023 Jun; 43(3):539-550. PubMed ID: 37119369 [TBL] [Abstract][Full Text] [Related]
26. Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms. Kurbacher CM; Horn O; Kurbacher JA; Herz S; Kurbacher AT; Hildenbrand R; Bollmann R Oncologist; 2015 Nov; 20(11):1333-41. PubMed ID: 26417039 [TBL] [Abstract][Full Text] [Related]
27. Abnormal placental development and early embryonic lethality in EpCAM-null mice. Nagao K; Zhu J; Heneghan MB; Hanson JC; Morasso MI; Tessarollo L; Mackem S; Udey MC PLoS One; 2009 Dec; 4(12):e8543. PubMed ID: 20046825 [TBL] [Abstract][Full Text] [Related]
28. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361 [TBL] [Abstract][Full Text] [Related]
29. EpCAM is up-regulated by EGF via ERK1/2 signaling and suppresses human epithelial ovarian cancer cell migration. Fan Q; Cheng JC; Qiu X; Chang HM; Leung PC Biochem Biophys Res Commun; 2015 Feb; 457(3):256-61. PubMed ID: 25576358 [TBL] [Abstract][Full Text] [Related]
30. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922 [TBL] [Abstract][Full Text] [Related]
31. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Høgdall EV; Høgdall CK; Christensen L; Glud E; Blaakaer J; Bock JE; Vuust J; Nørgaard-Pedersen B; Kjaer SK Anticancer Res; 2002; 22(3):1859-64. PubMed ID: 12168882 [TBL] [Abstract][Full Text] [Related]
32. Identification of EpCAM as the gene for congenital tufting enteropathy. Sivagnanam M; Mueller JL; Lee H; Chen Z; Nelson SF; Turner D; Zlotkin SH; Pencharz PB; Ngan BY; Libiger O; Schork NJ; Lavine JE; Taylor S; Newbury RO; Kolodner RD; Hoffman HM Gastroenterology; 2008 Aug; 135(2):429-37. PubMed ID: 18572020 [TBL] [Abstract][Full Text] [Related]
33. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216 [TBL] [Abstract][Full Text] [Related]
34. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216 [TBL] [Abstract][Full Text] [Related]
35. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Patriarca C; Macchi RM; Marschner AK; Mellstedt H Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002 [TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Li Y; Jin X; Kang S; Wang Y; Du H; Zhang J; Guo W; Wang N; Fang S Gynecol Oncol; 2006 Apr; 101(1):92-6. PubMed ID: 16278009 [TBL] [Abstract][Full Text] [Related]
37. Catumaxomab: a bispecific trifunctional antibody. Sebastian M; Kuemmel A; Schmidt M; Schmittel A Drugs Today (Barc); 2009 Aug; 45(8):589-97. PubMed ID: 19927225 [TBL] [Abstract][Full Text] [Related]
38. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Wimberger P; Gilet H; Gonschior AK; Heiss MM; Moehler M; Oskay-Oezcelik G; Al-Batran SE; Schmalfeldt B; Schmittel A; Schulze E; Parsons SL Ann Oncol; 2012 Aug; 23(8):1979-1985. PubMed ID: 22734013 [TBL] [Abstract][Full Text] [Related]
39. Association of heparanase gene (HPSE-1) single nucleotide polymorphisms with gastric cancer. Yue Z; Song Y; Wang Z; Luo Y; Jiang L; Xing L; Xu H; Zhang X J Surg Oncol; 2010 Jul; 102(1):68-72. PubMed ID: 20578081 [TBL] [Abstract][Full Text] [Related]
40. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro. Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]